Proliferation of sorted human and rat beta cells by Parnaud, G. et al.
ARTICLE
Proliferation of sorted human and rat beta cells
G. Parnaud & D. Bosco & T. Berney & F. Pattou &
J. Kerr-Conte & M. Y. Donath & C. Bruun &
T. Mandrup-Poulsen & N. Billestrup & P. A. Halban
Received: 23 May 2007 /Accepted: 18 September 2007 / Published online: 10 November 2007
# Springer-Verlag 2007
Abstract
Aims/hypothesis The aim of the study was to determine
whether purified beta cells can replicate in vitro and whether
this is enhanced by extracellular matrix (ECM) and growth
factors.
Methods Human beta cells were purified by FACS by virtue
of their high zinc content using Newport Green, and excluding
ductal and dead cells. Rat beta cells were sorted by
autofluorescence or using the same method developed for
human cells. Cells were plated on poly-L-lysine or ECMs
from rat or human bladder carcinoma cells or bovine corneal
ECM and incubated in the presence of BrdU with or without
growth factors.
Results The newly developed method for sorting human
beta cells yields a population containing 91.4±2.8% insulin-
positive cells with a low level of spontaneous apoptosis and a
robust secretory response to glucose. Beta cells from 8-
week-old rats proliferated in culture and this was increased
by ECM. Among growth factors, only human growth
hormone (hGH) and the glucagon-like peptide-1 analogue
liraglutide enhanced proliferation of rat beta cells, with a
significant increase on both poly-L-lysine and ECM. By
contrast, sorted adult human beta cells from 16 donors aged
48.9±14.3 years (range 16–64 years) failed to replicate
demonstrably in vitro regardless of the substratum or
growth factors used.
Conclusions/interpretation These findings indicate that, in
our conditions, the fully differentiated human adult insulin-
producing beta cell was unable to proliferate in vitro. This
has important implications for any attempt to expand cells
from pancreases of donors of this age group. By contrast,
the rat beta cells used here were able to divide in vitro, and
this was enhanced by ECM, hGH and liraglutide.
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Introduction
As the availability of human donors for pancreatic islet
transplantation is limited, there is an urgent need for
alternative sources. In vitro expansion of adult human beta
cells may provide an adequate source for beta cell therapy,
but little is known about their proliferative capacity.
The extracellular matrix (ECM) is a complex structural
entity surrounding cells within mammalian tissues that is able
to regulate many essential cellular functions, including
proliferation [1–4]. ECM produced by 804G (rat bladder
carcinoma) cells thus improves glucose-stimulated insulin
secretion (GSIS) and survival of primary rat beta cells [5–7].
Furthermore, this ECM or its human equivalent (HTB9-
ECM) increases replication of human endocrine islet and/or
duct cells [8–11].
Several growth factors have been shown to be mitogenic
for insulinoma cell lines [12–16], but their ability to promote
replication of adult beta cells has been less extensively
studied. The focus of this study was to understand whether
adult beta cells can replicate in vitro, and if so whether this
can be enhanced by ECM and growth factors.
Methods
Rat islet isolation and beta cell purification Animal
experimentation conformed to the guide for the care and use
of laboratory animals and was authorised by the Veterinarian
Office of Canton de Geneve (Geneva, Switzerland). Islets were
isolated by collagenase digestion of pancreases from 2- or
18-month-old male Wistar rats (Janvier, Le Genest-St-Isle,
France), followed by Ficoll purification as described [17]. Islets
were trypsinised and beta cells purified using a FACStar-Plus
(Becton Dickinson, Sunnyvale, CA, USA) as described [18,
19] by autofluorescence or by virtue of their zinc content
using the zinc-binding fluorochrome Newport Green (NG).
Human beta cell purification Human islets (average age of
cadaveric donors 48.9±14.3 years; range 16–64 years; n=16)
were provided through the Juvenile Diabetes Research
Foundation (JDRF) Islet Distribution Program by Islet Cell
Resource Centers in Geneva (Switzerland), Milan (Italy) and
Lille (France). The use of human tissue for research was
approved by our local institutional ethical committee.
Single cell suspensions were obtained by incubating (37°C,
10 min) islets in Accutase (PAA Laboratories GmbH, Colbe,
Germany). The dispersed cells were washed with modified
Krebs–Ringer bicarbonate HEPES buffer (KRBH:
125 mmol/l NaCl, 4.74 mmol/l KCl, 1 mmol/l CaCl2,
1.2 mmol/l KH2PO4, 1.2 mmol/l MgSO4, 5 mmol/l NaHCO3,
25 mmol/l HEPES, pH 7.4, 0.5% BSA) containing
2.8 mmol/l glucose and resuspended in this buffer. Cells
were incubated (1 h, 4°C) with mouse anti-pan-ductal
membrane carbohydrate antigen 19-9 (CA19-9) antibody
(1 μg/ml; NovoCastra, Newcastle upon Tyne, UK), rinsed
twice with KRBH and reincubated for 1 h with Alexa-Fluor
633 anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). After washing, cells were resuspended in KRBH
containing 1.5 μl/ml Pluronic F127 and incubated (30 min,
37°C) with 1 μmol/l NG-PDX-Ac (Molecular Probes,
Leiden, The Netherlands). After washing, cells were stained
10 min with 7-amino-actinomycin-D (7-AAD, 10 μg/ml;
Molecular Probes). Analysis and cell sorting were performed
using a FACSvantage (Becton Dickinson). Beta cells were
enriched in the 7-AAD-negative, CA19-9-negative and NG-
bright populations.
ECMs ECM from 804G cell-conditioned medium was
prepared and used as described previously [6]. For lawns of
lysed cells, HTB9 (human bladder carcinoma) cells were
grown to confluency and then lysed by exposure for 10 min
to 0.1 mol/l NH4OH followed by washes with H2O (adapted
from [20]). Coated Petri dishes were stored at 4°C after air-
drying. Before use, dishes were washed once again and
dried. Bovine corneal ECM (BC-ECM)-coated plasticwares
were from Biological Industries (Kibbutz Beit Haemek,
Israel). Dishes coated with poly-L-lysine (PLL; 100 μg/ml)
were used as control.
Culture of cells Culture medium for rat beta cells was
DMEM (Gibco, Invitrogen, Basel, Switzerland), 10% FCS,
11.2 mmol/l glucose, 1 mmol/l sodium pyruvate, 110 U/ml
penicillin, 110 μg/ml streptomycin and 50 μg/ml gentamicin.
For human beta cells, medium was CMRL 1066, 10% FCS,
1% glutamine, 5.6 mmol/l glucose, 1 mmol/l HEPES and
antibiotics as above. Sorted cells were washed with appropri-
ate medium and incubated (20 h, 37°C) in non-adherent
100 mm diameter Petri dishes to allow recovery from cell
purification. Cells were resuspended at 4×105 cells/ml in
medium, and 50 μl droplets deposited on coated dishes.
Intact human islets were similarly deposited as droplets (ten
islets per dish). In each instance, after 24 h, 2 ml culture
medium were added to the droplets.
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Immunofluorescence Sorted cells were attached (90 min) to
PLL-coated Cunningham’s chambers and then fixed (4%
paraformaldehyde [wt/vol.], 20 min). After washing (PBS),
cells were incubated (PBS/0.5% Triton X-100 [wt/vol.],
4 min), rinsed (PBS), preincubated (30 min, room temper-
ature) in PBS/0.5% BSA (wt/vol.) and exposed for 2 h (room
temperature) to guinea pig anti-insulin serum (DB, Univer-
sity of Geneva, Switzerland) and rabbit anti-glucagon
antibody (Dako, Baar, Switzerland). After three washes they
were incubated (1 h, room temperature) with FITC-
conjugated goat anti-rabbit or rhodamine-conjugated goat
anti-guinea pig antibodies diluted in PBS/0.5%BSA (wt/vol.).
Samples were examined by fluorescence microscopy (Carl
Zeiss, Feldbach, Switzerland).
Short-term GSIS Beta cells were washed three times with
KRBH, 2.8 mmol/l glucose and preincubated (1 h, 37°C)
with this same buffer, followed by successive 1 h incuba-
tions at 37°C in KRBH with 2.8 and 16.7 mmol/l glucose
for rat beta cells or 22.2 mmol/l glucose for human beta
cells. When indicated, growth factors were added directly
in KRBH containing 16.7 mmol/l glucose. Cellular insulin
was extracted with acid–ethanol, and insulin in buffers and
extracts measured by RIA with rat or human insulin as the
standard. Total insulin is the sum of extracted insulin and
insulin secreted during the two incubations.
Detection of proliferation by immunofluorescence Islets or
sorted beta cells were incubated with 10 μmol/l BrdU for
1–6 days. They were fixed (1% paraformaldehyde [wt/vol.],
1 h room temperature) and DNA denatured (1.5 mol/l HCl).
After permeabilisation (PBS/0.5% Triton X-100 [wt/vol.],
4 min), proliferation was estimated using an immunohisto-
chemical assay kit as described by the manufacturer (BrdU
Labelling and Detection Kit; Roche, Basel, Switzerland). For
Ki-67 staining, cells were fixed after 2–9 days of culture,
washed (PBS), permeabilised (PBS/0.1% Triton X-100 [wt/
vol.], 10 min), rinsed (PBS), preincubated (30 min, room
temperature) in PBS/1% BSA (wt/vol.) and stained with
mouse anti-Ki-67 (BD Pharmingen, Basel, Switzerland) for
2 h (room temperature), followed by Alexa-fluor 533-
conjugated anti-mouse Ig. Cells were also co-stained for
insulin or for pancreatic and duodenal homeobox 1 (PDX1;
goat anti-PDX1; kind gift from C. V. Wright, Vanderbilt
University, Nashville, TN, USA). Following washing, cells
were incubated with Alexa-fluor 488-conjugated anti-guinea
pig or anti-goat Ig. Nuclei were stained with 10 μg/ml DAPI
(Sigma-Aldrich, Buchs, Switzerland). The percentage of cells
double-positive for insulin+BrdU or PDX1+BrdU per total
number of insulin- or PDX1-single-positive cells, respectively,
was calculated.
To study effects of exogenous growth factors, beta cells
were cultured for 1–5 days with 40 nmol/l of the long-acting
glucagon-like peptide-1 (GLP-1) analogue liraglutide,
0.5 μg/ml EGF, 2 μmol/l gastrin, 400 ng/ml human growth
hormone (hGH) (the generous gift of Novo Nordisk,
Bagsvaerd, Denmark; concentrations were as recommended
by the supplier and in the range of concentrations used by
others [21]) and 2 nmol/l betacellulin (Sigma Buchs; a
concentration that had been shown to increase DNA
synthesis in human fetal islet-like cell clusters [22]).
Data analysis Data are means±SEM for n independent
experiments (using cells from separate islet isolations) unless
specified otherwise. Statistical significance was tested by
Student’s unpaired t test with p<0.05 considered significant.
Results
Effect of ECM on rat beta cell proliferation To study the
impact of ECM on proliferation, rat beta cells were plated
on 804G-ECM or PLL (control), using standard culture
conditions (DMEM, 10% FCS, 11.2 mmol/l glucose). Beta
cell proliferation was then measured by BrdU incorporation
followed by immunostaining for BrdU and insulin or
PDX1. Rat beta cells that had divided (BrdU-positive)
continued to store insulin (Fig. 1a) and to express PDX1
(Fig. 1b) and they proliferated on both substrates. Interest-
ingly, 804G-ECM significantly increased proliferation of
rat beta cells at all times vs PLL (Fig. 1c).
Before performing similar experiments on human beta
cells, we determined the effect of lysed HTB9 lawns, an ECM
used for human beta cells, on rat beta cell replication and
GSIS. HTB9-ECM induced spreading of rat beta cells (data
not shown) and GSIS was significantly increased to the same
extent as for cells on 804G-ECM compared with PLL
(Fig. 2a). HTB9-ECM also significantly increased the
proliferation of rat beta cells vs PLL, but this increase was
less than that induced by 804G-ECM (Fig. 2b). Rat beta cells
also proliferated in CMRL 1066, the medium routinely used
for human beta cells (data not shown). Furthermore, BC-
ECM increased spreading and proliferation of rat beta cells
by 2.8±0.3-fold compared with PLL (p=0.005).
Purity of human beta cell preparations Since it proved
impossible to obtain a suitably enriched population of human
beta cells using the same (autofluorescence) method as for rat
cells, we adapted and combined previously published tech-
niques [23–25] for this purpose, neither of which proved
satisfactory alone. After dissociation of islets, human ductal
cells were specifically labelled using anti-CA19-9 antibody,
beta cells were labelled with NG (due to their high zinc
content) and dead cells were labelled with 7-AAD, which
binds to DNA when cell membrane permeability is altered
after cell death. Cells were then analysed by FACS.
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After exclusion of 7-AAD- and C19-9-positive cells, two
populations of cells were gated and sorted, according to
their side scatter patterns and fluorescence (Fig. 3a): R5,
high scatter/high NG fluorescence; R4, low scatter/low NG
fluorescence. These sorted cell populations were analysed
by immunofluorescence for insulin staining. The high NG-
positive population (R5) appeared highly enriched in beta
cells, while R4 was poor in beta cells (Fig. 3b), with other
endocrine and non-endocrine cells. R5 comprised 91.4±
2.8% insulin-positive and 3.9±2.5% glucagon-positive cells
compared with 42.6±7.8% and 20.5±7.6%, respectively,
for the original unsorted cells (n=7–9). Population R5,
henceforth called ‘human beta cells’, survived well and
showed very low levels of spontaneous apoptosis (<1%; not
shown) after 10 days in culture.
To determine whether the NG sorting method could
impact beta cell proliferation, rat beta cells sorted by this
method were compared with those sorted by autofluores-
cence. Proliferation was similar and 804G-ECM signifi-
cantly increased cell proliferation in both instances
(Electronic supplementary material Fig.1).
Effect of ECM on human beta cell proliferation To study
proliferation of sorted human beta cells we used plastic
dishes coated with 804G-ECM, lysed HTB9 lawns or
commercial BC-ECM as substrates. As for rat beta cells,
human beta cells spread on all matrices tested (HTB9-,
804G- or BC-ECM), contrary to beta cells plated on PLL,
which remained round. However, unlike for rat cells, GSIS
was similar for human beta cells plated on PLL or on these
different matrices (Fig. 4a). Furthermore, no cell replication
was observed in human beta cells under any of these
conditions (Fig. 4b), despite assays being performed on five
independent isolations with more than 300,000 beta cells
analysed. These experiments were performed with CMRL
1066 medium complemented with 10% FCS generally used
for culturing human islets. However, we also investigated
human beta cell replication in RPMI and DMEM medium
containing 10% FCS or 2% human serum, and again no
beta cell proliferation was detected (data not shown).
To test whether sorting of human beta cells affects their
proliferation, we measured beta cell replication in isolated
human islets that had not been trypsinised (intact) and
where beta cells are in a more physiological environment.
Figure 5 shows a representative experiment of six experi-
ments. After 2–3 days, some islets were spread on HTB9-
ECM while the majority remained intact. In such intact
unspread islets, BrdU-positive cells were observed (Fig. 5a)
but confocal microscopy revealed that these BrdU-positive
cells were always insulin-negative (Fig. 5b). Similar results
were obtained with spread islets and after trypsinisation of
intact islets and attachment of the single cell suspension,
with BrdU-positive cells being systematically insulin-
negative (Fig. 5c; about 100,000 cells obtained from three
different islet preparations were analysed).
To investigate the hypothesis that human beta cells can
lose insulin labelling during replication (perhaps by
degranulation), we labelled beta cells for PDX1, a tran-
scription factor expressed by beta cells in adult islets. After
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Fig. 2 Effect of HTB9-ECM on rat beta cell proliferation. Rat beta
cells were attached to either PLL, 804G-ECM or lawns of NH4OH-
lysed HTB9 cells (HTB9-ECM) and cultured for 2 days in DMEM,
10% FCS, 11.2 mmol/l glucose, with the last day in the presence of
BrdU (10 μmol/l). a Short-term (1 h) insulin secretion in response to
2.8 mmol/l glucose (white bars) and 16.7 mmol/l glucose (black bars)
was then analysed. Data (means±SEM of 3–4 independent experi-
ments) are expressed as percentage of total (secretion plus content). b
Beta cell proliferation. Means±SEM, n=3 independent experiments.
**p<0.01 vs PLL control; §p<0.03 vs 804G-ECM
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Fig. 1 Effect of 804G-ECM on rat beta cell proliferation. Rat beta cells
sorted by autofluorescence were attached to either PLL or 804G-ECM.
After 24 h of culture (DMEM, 10% FCS, 11.2 mmol/l glucose) cells were
cultured for 1, 4 or 6 days in the continuous presence of BrdU (10 μmol/
l). Immunofluorescence for BrdU (proliferation) and insulin (beta cells)
was performed and the number of BrdU-positive beta cells was
determined. a, b Representative micrographs of beta cells plated on
804G-ECM incubated with BrdU for 2 or 4 days, respectively, and
stained for BrdU (red nuclei in a and b), insulin (green in a and blue in
b) or PDX1 (green nuclei in b). Nuclei (blue in a) were stained with
Hoechst 33342. Bar, 10 μm. c Quantitative data expressed as the
percentage of insulin-positive cells that were also BrdU positive.
Means±SEM, n=3–4 independent experiments; **p<0.01 vs its
respective PLL control; §p<0.03 vs PLL control. White bars, 1 day;
grey bars, 4 days; black bars, 6 days
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4 days in the presence of BrdU, we failed to observe any
colocalisation between BrdU and PDX1 (Fig. 5d) either in
>500,000 sorted beta cells or in approximately 200 intact
islets obtained from four islet preparations that were
evaluated in this regard.
With increasing culture time we observed the appearance
of fibroblastoid- or mesenchymal-like cells with a large
oval nucleus in sorted beta cells and in (unsorted) dispersed
islet cell populations. Most of these cells were BrdU-
positive (Fig. 5d) and were far more abundant in dispersed
islet cells. These cells were systematically negative for
insulin or PDX1.
Finally, we also stained human and rat beta cells with
Ki-67 as an alternative means of identifying proliferating
cells. As shown in Fig. 6a,b, after 48 h of culture on 804G-
ECM, Ki-67-positive rat beta cells that continued to express
insulin or PDX1 were detected. However, with sorted
human beta cells or with human islets, cultured during 3–
9 days, we could not observe coexpression of Ki-67 and
insulin or PDX1 (Fig. 6c–f).
Effect of growth factors on beta cell proliferation and
insulin secretion To try to stimulate beta cell proliferation,
sorted beta cells as well as islets attached to ECM were
incubated with betacellulin, EGF, gastrin, the GLP-1
analogue liraglutide or hGH for 1–10 days. Growth factors
alone or in combination did not induce proliferation of
human beta cells even in intact islets (data not shown;
experiments were performed with eight different isolations).
By contrast, hGH led to an approximately twofold increase
of rat beta cell replication after 24 h, in both cells plated on
PLL and on 804G-ECM (Fig. 7a), while liraglutide, EGF,
gastrin and betacellulin had no significant effect. EGF and
betacellulin did, however, increase the growth of human
mesenchymal-like cells (data not shown). However, when
we extended the culture time to 48 h, rat beta cell
proliferation was significantly increased by liraglutide on
PLL and on 804G-ECM (Fig. 7b). Nevertheless, even in the
presence of hGH or the GLP-1 analogue, we still observed
a significant increase of cell replication on 804G-ECM
when compared with PLL, indicating an additive effect.
Since human beta cell replication could not be stimulated
by the growth factors, it was possible that they were
unresponsive in all respects to these agents. To investigate
this, we tested their effect on insulin secretion. As expected,
liraglutide significantly increased insulin secretion from
both rat and human beta cells plated either on PLL or on the
different matrices (Fig. 7c,d). For rat beta cells, hGH had a
minor but significant effect on GSIS both on cells plated on
PLL and on 804G-ECM (Fig. 7c).
Effect of age on rat beta cell proliferation To investigate
the hypothesis that age can influence the proliferative
capacity of beta cells, we also analysed beta cell prolifer-
ation from 18-month-old rats. Beta cells obtained from 18-
month-old rats proliferated in culture and 804G-ECM
increased this proliferation (0.84±0.37% BrdU-positive
beta cells on PLL vs 2.87±0.1% on 804G-ECM; 24 h
incubation with BrdU; mean±SD, n=2 independent experi-
ments). However, in this limited series of experiments, beta
Fig. 3 FACS analysis of human
islet cells. a Single islet cells
were stained with anti-CA19-9
antibody (ductal marker), NG
(beta cells) and 7-AAD
(dead cells) and analysed
by FACS. Upper panel, 7-AAD;
middle panel, y-axis CA19-9,
x-axis NG; lower panel, gated
NG vs side scatter after
exclusion of 7-AAD- and
CA19-9-positive cells. Cells
were then sorted into NG-low
(R4) and -bright (R5) subsets.
b Immunofluorescence analysis
of cells before and after
sorting of the two subsets R4
and R5: insulin in green, nuclei
in blue. Bar, 100 μm. SSC,
side scatter pattern
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cells from these old rats did appear to proliferate less than
those from young (8-week-old) rats both on PLL and on
804G-ECM (1.96±0.01% and 4.85±0.97%, respectively).
Discussion
In this study we describe a new technique using NG
staining and autofluorescence-activated flow cytometry to
obtain a >90% pure and functional population of beta cells.
Using this and an established method for sorting rat beta
cells, we studied the effect of ECM in combination with
growth factors on beta cell proliferation. In previous studies
intact islets or islet cells more or less spread on ECM were
used to examine beta cell replication. In these conditions,
overlay of cells can lead to ambiguous labelling. Indeed the
report that human beta cells are able to replicate when
exposed to selected matrices and growth factors [26] was
challenged by others showing that these culture conditions
were mitogenic for duct cells and not for beta cells [11].
Using sorted human beta cells, and regardless of the culture
conditions (various ECMs with or without growth factors),
we failed to observe, according to our criteria, any bona
fide beta cells that are Ki-67-positive or that had incorpo-
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Fig. 4 Effect of ECM on sorted human beta cell proliferation. Sorted
human beta cells were attached to Petri dishes coated with either PLL,
804G-ECM, lawns of NH4OH-lysed HTB9 cells (HTB9-ECM) or
BC-ECM. a After 3 days of culture, short-term (1 h) insulin secretion
in response to 2.2 mmol/l glucose (white bars) and 22.2 mmol/l glucose
(black bars) was then analysed. Results (insulin secretion as percentage
total) are normalised to GSIS from cells on PLL, and expressed as
means±SEM, n=3–4 independent experiments. b After 4 days in the
continued presence of BrdU (10 μmol/l), human beta cells were
analysed by immunofluorescence for BrdU (red) and insulin (green).
Results revealed that none of the insulin-positive cells are BrdU-
positive (should be red). Nuclei (blue) were stained with Hoechst
33342. Bar, 30 μm
Fig. 5 Effect of ECM on beta cell proliferation in human islets or
non-sorted human islet cells. a, b Intact human islets attached to
HTB9-ECM and cultured for 9 days in the continued presence of
BrdU (10 μmol/l). a Two examples of BrdU-positive cells present in
an islet that had spread (left) or not (right) on HTB9-ECM. b One
example of Z-stack analysis showing that BrdU-positive cells were
insulin-negative. c Cell suspension obtained after trypsinisation of
islets but without sorting. d Intact human islets or purified human beta
cells cultured on HTB9-ECM for 5 days with BrdU (10 μmol/l)
present during the last 4 days. Images are confocal microscopy of
immunofluorescence. a–c BrdU, red; insulin, green; nuclei (Hoechst
33342), blue. d BrdU, red; PDX1, green. Bar, 30 μm
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rated BrdU even during prolonged (>10 days) culture. We
cannot exclude that an even longer time could be required
for proliferation to be induced. However, and in striking
contrast, beta cells from young rats were seen to proliferate
in vitro and this was significantly increased by ECM and
growth factors. The technique used to purify human beta
cells is not the cause, because rat beta cells, purified with
the same NG sorting method used for human cells, can
proliferate in a similar manner to when sorted using the
well-established autofluorescence method. Control experi-
ments further indicated that neither the ECM nor the
medium used for human beta cells was the cause.
Furthermore, it was not possible to detect beta cell
proliferation even in (intact) isolated human islets. To
exclude the fact that division of human beta cells could be
accompanied by rapid loss of insulin, we also performed
double immunostaining of BrdU or Ki-67 and PDX1. But
again no colocalisation of BrdU or Ki-67 with PDX1 was
observed in human beta cells, in contrast to results obtained
using rat beta cells.
The divergence between our data and those of Beattie et al.
[8–10] may be explained in part, by differences in methods.
In their studies, proliferation was on some occasions
quantified by 3H-labelled thymidine incorporation, which
determines the proliferation of all cells and not only beta
cells. However, on other occasions proliferating cells were
double-stained for insulin and BrdU [9] or Ki-67 [10]. As
discussed above, however, even with confocal microscopy it
is not easy to determine whether cells are truly double-
labelled or not if they are not in a veritable monolayer.
Beattie et al. conclude that the cells they identify as double-
positive are never ‘brightly stained’ for insulin [9, 10],
whereas upon close inspection of many such cells we
consider them to be insulin-negative. In our study we did
observe, as others in the past, a growing population of cells
that were BrdU- or Ki-67-positive, but it was apparent by
confocal microscopy that all of these cells were insulin or
PDX1-negative. Moreover these cells that closely resemble
the human islet-derived mesenchymal-like cells described by
others [27, 28] were more abundant when we cultured
dispersed islet cells rather than purified beta cells, suggesting
that they did not derive from beta cells by epithelial–
mesenchymal transition [27]. This supports recent studies
showing that mesenchymal cells emerging from mouse islets
are similarly not derived from beta cells [29–32]. Neverthe-
less, we cannot exclude from our studies that in human beta
cells proliferation is accompanied by the rapid loss of
characteristic features such as PDX1 and insulin expression
or that their expression is sufficiently attenuated as to make it
undetectable in our immunofluorescence conditions. This
issue could only be resolved by labelling human beta cells
with a stable marker that is not lost upon de-differentiation.
Double-positive cells (insulin and ductal markers) have been
observed in healthy and pathological human pancreases [33].
These cells may represent newly differentiated ductal
precursor cells as well as beta cells which have de-
differentiated towards a ductal precursor. Our technique for
sorting beta cells would have excluded such cells, but had
such cells proliferated in the unsorted islet cells or whole
islet preparations they would have been scored as ‘insulin-
positive’ cells, regardless of whether they also expressed
ductal markers: no such cells were detected. However,
interestingly, lineage tracing in mouse beta cells shows that
de-differentiation occurs but is not followed by proliferation
[32]. Furthermore, and although cells from 16 different
human pancreases were studied, with thousands of cells
screened in each preparation, we cannot exclude that adult
human beta cells can replicate under our conditions at a non-
detectably low rate or that other conditions may exist that
might allow for such proliferation.
ECM has been reported to enhance proliferation of other
cell types in vitro [34], but this is the first report to show
that primary rat beta cell proliferation is significantly
Fig. 6 Ki-67 expression in rat and human beta cells. Immunofluo-
rescence for Ki-67 (a marker of proliferation, red in all pictures) and
insulin (green in a, c, e) or PDX1 (green in b, d, f) was performed in
rat beta cells plated on 804G-ECM for 48 h (a, b), and in sorted
human beta cells (c, d) or human islets (e, f) plated on HTB9-ECM for
6 and 3 days, respectively. A number of cells displayed colocalisation
of Ki-67 and PDX1 or insulin in rat beta cells (arrows in a, b; the
boxes in lower right-hand corners are threefold magnifications of cells
coexpressing insulin or PDX1 and Ki-67). Colocalisation of Ki-67 and
PDX1 or insulin was not observed in human beta cells (c–f). Bar,
20 μm
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increased by ECM. The signal transduction mechanism
involved in this effect remains to be determined, but
integrins could play a role in this phenomenon as has been
demonstrated for insulin secretion [35].
Among the growth factors and hormones tested, only hGH
and the GLP-1 analogue significantly increased adult rat beta
cell proliferation. hGH levels rise during pregnancy and
lactation, states that are associated with an expansion of the
beta cell mass [36, 37], and hGH is one of the most potent
mitogenic stimuli for rat beta cells even if its effect is greater
in neonatal than in adult rat [38, 39]. hGH was shown many
years ago to stimulate human islet cell proliferation [38].
However, direct comparison with the present study is not
possible for several reasons. First, incorporation of BrdU into
all islet cells was quantified in the older study, without
identification of cell type. Furthermore, only two human islet
preparations were studied for their proliferation and hGH
only increased proliferation in one. Although it is intriguing
to note that these hGH-responsive islets were from a
relatively young (16-year-old) female donor pancreas, while
the other was from a 49-year-old female, it is impossible to
draw any conclusions from such a limited sample set.
In our study, the GLP-1 analogue liraglutide significantly
increased proliferation of rat beta cells only after 48 h but
not 24 h of treatment, but instantly increased GSIS, in
keeping with its well known insulinotrophic action [40–43].
Several in vitro studies have also shown that GLP-1 and its
analogues are capable of inducing beta cell proliferation in
rodent islets and insulinoma cell lines [14, 21, 41]. The
proliferative effects of GLP-1 appear to involve multiple
cellular pathways which may involve transcriptional induc-
tion of cyclin D1 [21]. Furthermore, GLP-1 also induces
Pdx1 gene expression [44]. Taken together, GLP-1 could
induce gene expression necessary for cell division, possibly
explaining the need for a 48 h exposure to the hormone.
The effect of ECM on proliferation seemed to be
additive to that of either hGH or liraglutide, suggesting an
independent mode of action. In this study, betacellulin did
not increase rat or human beta cell replication even though
this member of the EGF family has been identified as a beta
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Fig. 7 Effect of growth factors on beta cell proliferation and insulin
secretion. a, b Rat beta cells were attached to either PLL (white bars)
or 804G-ECM (black bars) and proliferation, measured as described
in the legend to Fig. 1, was normalised to PLL. After an initial period
of 24 h, cells were cultured for 24 h with BrdU (10 μmol/l) in the
presence of different growth factors (a) or for 48 h in the presence of
the GLP-1 analogue liraglutide with the last day in the presence of
BrdU (10 μmol/l) (b). Means±SEM, n=3–5 independent experi-
ments; *p<0.05 vs PLL control; †p<0.05 vs 804G-ECM control. c
After an initial period of 24 h, rat beta cells were cultured on PLL or
on 804G-ECM (ECM) for 24 h in the presence of different growth
factors. Short-term (1 h) insulin secretion in response to 2.8 mmol/
l glucose (white bars) and 16.7 mmol/l glucose (black bars) in the
presence of growth factors was then measured. Means±SEM, n=3–4
independent experiments; *p<0.05 vs PLL control; **p<0.01 vs
804G-ECM control. d Short-term (1 h) insulin secretion of human
beta cells in response to 2.2 mmol/l (white bars) and 22.2 mmol/
l glucose (black bars) in the presence of liraglutide was analysed after
3 days of culture with liraglutide. Means±SEM, n=3 independent
experiments; **p<0.01 vs its respective control
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cell mitogen in INS-1 cells [16]. But in fact, in the rat
RINm5F cell line, and also in fetal human beta cells,
betacellulin failed to induce proliferation [16, 22], suggest-
ing that the type and stage of development of the cells used
can influence the outcome.
The discrepancy between the results obtained in rat and
human beta cells, apart from an intrinsic species difference,
could be explained by the age of the pancreas used for islet
isolation (for most experiments, rat beta cells were obtained
from 8-week-old animals whereas human beta cells were
obtained from patients with an average age of 49 years). This
hypothesis is supported by recent work from others demon-
strating slower beta cell turnover in aged mice [45] or rats
[46], and is favoured by our own results suggesting a lower
proliferative capacity in beta cells isolated from 18-month-old
rats even though the limited number of experiments does not
allow for statistical analysis. Nevertheless, the old rat beta
cells did proliferate in vitro in marked contrast to human beta
cells (from all donors in the present study, spanning the range
16–64 years of age). Therefore, it seems that the observed
discrepancy between rat and human beta cells probably
reflects the combination of species as well as age differences.
Regardless, the purpose of this study was not to compare beta
cell proliferation from age-matched rat and human pancreases,
but rather to evaluate the proliferative capacity of fully
differentiated human beta cells from donors within the typical
age range used for transplantation or experimental purposes.
Rat beta cells were used as a positive control. Our (negative)
results using human beta cells in our experimental setting
have important implications for any attempt to expand cells
from pancreases of donors of this age group (16–64 years).
In summary, rat beta cells can proliferate in vitro. This is
significantly increased by ECM with a further additive
increase by hGH and a GLP-1 analogue. Indeed and
strikingly, after 6 days of continuous culture with BrdU, more
than half of the cells on 804G-ECM had become labelled with
BrdU (60.44±3.08%, n=3), an extraordinarily high number
for a fully differentiated cell type long considered essentially
quiescent. By contrast, in this study using islets from
cadaveric organ donors above the age of 16 years, we failed
to detect replication of the fully differentiated human adult
beta cell in vitro regardless of whether they had been sorted
by FACS or not, and of the culture environment. While these
negative data do not allow us to draw any conclusions
regarding in situ beta cell regeneration in vivo in adult
humans, and the possible beneficial effects of factors such as
GLP-1 in such a context, they do have important implica-
tions for any attempt to grow such cells in culture with a
view to obtaining increased numbers for transplantation.
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